CWM
CRL icon

Compass Wealth Management’s Charles River Laboratories CRL Stock Holding History

Compass Wealth Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-233
Closed -$35.1K – 201
2025
Q1 		$35.1K Hold
233
– – 0.01% 275
2024
Q4 		$43K Sell
233
-466
-67% -$89.8K 0.01% 261
2024
Q3 		$138K Hold
699
– – 0.03% 179
2024
Q2 		$144K Buy
699
+675
+2,813% +$153K 0.04% 175
2024
Q1 		$6.5K Hold
24
– – ﹤0.01% 363
2023
Q4 		$5.67K Sell
24
-150
-86% -$29.5K ﹤0.01% 357
2023
Q3 		$34.1K Hold
174
– – 0.01% 271
2023
Q2 		$36.6K Sell
174
-190
-52% -$37.8K 0.01% 272
2023
Q1 		$73.5K Sell
364
-110
-23% -$24.9K 0.02% 208
2022
Q4 		$103K Buy
+474
New +$104K 0.03% 184

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Compass Wealth Management's CRL Position: Q2 2025 in Review

Compass Wealth Management sold out of Charles River Laboratories (CRL) in Q2 2025, closing a stake of 233 shares — an estimated $35.1K sold.

Compass Wealth Management first reported a position in CRL in Q4 2022 and held it in 10 quarters. The position peaked at $144K in Q2 2024. 519 funds tracked by Wall St. Rank hold CRL as of Q2 2025.

  • Compass Wealth Management reported no remaining Charles River Laboratories position as of Q2 2025 after selling out during the quarter.
  • Compass Wealth Management sold 233 Charles River Laboratories shares in Q2 2025, an estimated $35.1K.
  • Compass Wealth Management first reported a position in Charles River Laboratories in Q4 2022 and held it in 10 quarters.
  • Compass Wealth Management's Charles River Laboratories position peaked at $144K in Q2 2024.
  • 519 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2025.

Based on Compass Wealth Management's 13F filing for Q2 2025, filed 8 Aug 2025.